Marco Demaria

Gerontologist, senescence aficionado and associate professor @ European Research Institute for the Biology of Ageing (ERIBA). Opinions are mine

[Nature Aging @NatureAging]

Online now! Cerrato et al propose a consensus roadmap towards precision senescence medicine, emerging from the SENESCENCE2030 meeting in Coimbra, Portugal earlier this year @marc_dema https://t.co/pgMKLOYtrp

[British Society for Research on Ageing @BSRAgeing]

🧬 Senescent cells accumulate as we age, can we understand them for better therapies?

@marc_dema will explore how understanding senescence could help develop new approaches to healthier ageing at #BSRA2026

🗓️ 9–11 Sept
📍 Keble College, Oxford
🔗https://t.co/0FOTFr0aRd

[Nature Aging @NatureAging]

Online now!✨Wang et al report a role for CDK4/6 in regulating not only cell cycle progression but also the SASP, via retinoic acid signaling and NFkB. Targeting this pathway reduces inflammation and improves function in aged mice @Marc_dema https://t.co/e5PnvbjcK8

[Phaedon Institute @PhaedonInstitut]

We are pleased to announce the Senotherapeutics Biomarker Consortium (SBC) Inaugural Summit, taking place on December 7, 2026 at the Clark Center Auditorium, Stanford University.

Registration is now open: https://t.co/aJ5SCgLunu

#PhaedonInstitute #SBC2026 #Senescence #Longevity

[Marco Demaria @marc_dema]

@metapredict @aiims_newdelhi Hi Jamie, I'm not the editor of npj aging since end of 2024. Never seen or handled this manuscript

[CeMM @CeMM_News]

Thank you, @marc_dema (@umcg) for a great #CeMMinar on heterogeneity in cellular #senescence! He shared how senescent cells can both aid tissue repair & drive aging & dysfunction, & how targeting them could support healthy #aging. Thanks to hosts @rooij_laura & André Rendeiro!

[TimePie (focus on anti-aging science) @TimePieChina]

Removing p16⁺ senescent cells rejuvenates female liver profiles—boosting mitochondrial function and reducing inflammation, mimicking effects of calorie restriction, #rapamycin, and #acarbose, a new study finds. #senescence
By Yao Lin, @marc_dema, et al.
https://t.co/MFjeX6cEEL

[Nature Reviews Cancer @NatureRevCancer]

#Comment on the accelerated aging phenotype in cancer survivors by Marc Demaria @marc_dema
Read it here: https://t.co/EmtEl3CbJ4

[Aging Journal @AgingJrnl]

We were proud to sponsor a poster prize at the ICSA Conference & Senotherapeutics Summit in Rome, co-organized by our EIC @marc_dema.

🎉 Congrats to Cheng Chen (Pasteur Institute, Paris), prize winner for her work on senescent FAPs in muscle regeneration!

#ICSA2025 #Aging

[Aging Journal @AgingJrnl]

Aging-US supports a milestone event for the global senescence & aging research community. @marc_dema

🗓️ September 16-19, Rome:
🔹10th Annual ICSA Conference
🔹2nd Phaedon Senotherapeutics Summit

Learn more and register ⬇️
https://t.co/PNBATshYsY

#ICSA2025 #Aging #Longevity

[Marco Demaria @marc_dema]

Super excited to invite you to #ICSA2025 in Rome– September 16-19!
This will be a special edition—celebrating 10 years of ICSA, and joining forces with the Phaedon Institute for a full day dedicated to senotherapeutics! https://t.co/exQqH3RjHh
#Senescence #LongevityScience #Aging

[Marco Demaria @marc_dema]

Can aging biology reshape healthcare?
In my latest editorial for @AgingJrnl , I argue it's time to shift from reactive disease treatment to proactive, biology-driven strategies that extend healthspan.
https://t.co/pfNBlLbLd9
#AgingResearch #Healthspan #Geroscience #Longevity

[Aging Journal @AgingJrnl]

"I am committed to advancing the journal’s mission by promoting rigorous science and encouraging interdisciplinary dialogue that bridges basic biology with clinical relevance." - @marc_dema

Read the full message from our new Editor-in-Chief:
🔗 https://t.co/cquuS1cKcp

#aging

[Aging Journal @AgingJrnl]

📢#CallforPapers: Aging (Aging-US) invites #submissions on cellular #senescence - its mechanisms, functions & clinical applications - in memory of Dr. Judith Campisi. @marc_dema

📅Deadline: January 15, 2026

🔗Submission Details:
https://t.co/L8Gs56zGqW

#AgingResearch #oa

[Aging Journal @AgingJrnl]

Our Longevity & Aging Series hosted by @EvgenyGalimov is a Finalist for a 2025 EPIC Award in the Video/Film category! Grateful to be recognized alongside so many talented professionals. #ScholarlyPublishing
@marc_dema @elevatemginc

https://t.co/Tx8ANeLL6h

#Aging #Longevity

[Aging Journal @AgingJrnl]

📢#CallforPapers: Aging (Aging-US) is honoring @Blagosklonny with a special #collection.

Submit your #research, reviews and perspectives on mTOR, rapamycin, #aging, cancer & more.

📅Deadline: December 1, 2025

🔗Submission Details:
https://t.co/0JerApWcNd

#agingresearch

[Marco Demaria @marc_dema]

Check out my recent comment https://t.co/wsrbKQoLop on the accelerated aging phenotype in cancer survivors. With increasing survivorship, understanding & addressing this issue is critical to improve quality of life. Free full access: https://t.co/BwphZmhPgd #Longevity #Aging

[Marco Demaria @marc_dema]

At https://t.co/rjA2hB4aOc we're seeking original research, reviews & perspectives on aging & age-related diseases, including:
- Biology of aging
- Translational & clinical research
- Epidemiology & multi-morbidity
Submit your best work!
#AgingResearch #Longevity #AgingUS

[Marco Demaria @marc_dema]

We believe this strategy could help eliminate therapy-induced senescent(-like) cancer cells, reducing recurrence & improving outcomes. Hopefully some funding agency will hep us to extend our study for pre-clinical validations and for applications in other tumor types

[Marco Demaria @marc_dema]

Excited to share our latest https://t.co/7COOKwrix9 revealing a novel approach to enhance the efficacy of CDK4/6 inhibitors in breast cancer treatment based on targeting aberrant lysosomes #BreastCancer #Senescence #CDK4_6Inhibitors #EMBOJournal #Senolytics #Aging #Longevity

[Marco Demaria @marc_dema]

We show that:
CDK4/6i induces a senescent-like state in breast cancer cells but these cells resist common senolytics;
Lysosomal alterations make them vulnerable to lysosomotropic agents (LLOMe, salinomycin);
Sequential treatment reduces tumor growth in HR+ & some TNBC models